Literature DB >> 33461259

[Mechanism of gut-microbiota-liver axis in the pathogenesis of intestinal failure-associated liver disease].

S X Fan1, J Wang2, Q Li1, Y S Li3, W X Guan1, J S Li2.   

Abstract

Intestinal failure (IF) is defined as the critical reduction of functional intestines below the minimum needed to absorb nutrients and fluids, so that intravenous supplementation with parenteral nutrition (PN) is required to maintain health and/or growth. Although the benefits are evident, patients receiving PN can suffer from serious cholestasis due to lack of enteral feeding and small intestinal bacterial overgrowth (SIBO). One such complication that may arise is intestinal failure-associated liver disease (IFALD). Evidences from recent studies suggest that alterations in the intestinal microbiota, as well as intraluminal bile acid driven signaling, may play a critical role in both hepatic and intestinal injury. Since Marshall first proposed the concept of the gut-liver axis in 1998, the role of gut-liver axis disorders in the development of IFALD has received considerable attention. The conversation between gut and liver is the key to maintain liver metabolism and intestinal homeostasis, which influences each other and is reciprocal causation. However, as a "forgotten organ" , intestinal microbiota on the pathogenesis of IFALD has not been well reflected. As such, we propose, for the first time, the concept of gut-microbiota-liver axis to emphasize the importance of intestinal microbiota in the interaction of gut-liver axis. Analysis and research on gut-microbiota-liver axis will be of great significance for understanding the pathogenesis of IFALD and improving the prevention and treatment measures.

Entities:  

Keywords:  Gut-liver axis; Gut-microbiota-liver axis; Intestinal failure; Intestinal failure-associated liver disease; Short bowel syndrome

Year:  2021        PMID: 33461259     DOI: 10.3760/cma.j.cn.441530-20201009-00550

Source DB:  PubMed          Journal:  Zhonghua Wei Chang Wai Ke Za Zhi        ISSN: 1671-0274


  2 in total

1.  Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.

Authors:  Yuanshe Huang; Xiaodong Wang; Lai Zhang; Ke Zheng; Jie Xiong; Jing Li; Chunlei Cong; Zhaomiao Gong; Jingxin Mao
Journal:  Comput Math Methods Med       Date:  2022-05-30       Impact factor: 2.809

2.  Ruminant fat intake improves gut microbiota, serum inflammatory parameter and fatty acid profile in tissues of Wistar rats.

Authors:  Larissa de Brito Medeiros; Susana Paula Almeida Alves; Rui José Branquinho de Bessa; Juliana Késsia Barbosa Soares; Camila Neves Meireles Costa; Jailane de Souza Aquino; Gerlane Coelho Bernardo Guerra; Daline Fernandes de Souza Araújo; Lydiane Tavares Toscano; Alexandre Sérgio Silva; Adriano Francisco Alves; Mateus Lacerda Pereira Lemos; Wydemberg José de Araujo; Ariosvaldo Nunes de Medeiros; Celso José Bruno de Oliveira; Rita de Cassia Ramos do Egypto Queiroga
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.